Literature DB >> 28017972

Herpes Genitalis: Diagnosis, Treatment and Prevention.

A Sauerbrei1.   

Abstract

Herpes genitalis is caused by the herpes simplex virus type 1 or type 2 and can manifest as primary or recurrent infection. It is one of the most common sexually transmitted infections and due to associated physical and psychological morbidity it constitutes a considerable, often underestimated medical problem. In addition to providing the reader with basic knowledge of the pathogen and clinical presentation of herpes genitalis, this review article discusses important aspects of the laboratory diagnostics, antiviral therapy and prophylaxis. The article is aimed at all health-care workers managing patients with herpes genitalis and attempts to improve the often suboptimal counselling, targeted use of laboratory diagnostics, treatment and preventive measures provided to patients.

Entities:  

Keywords:  antiviral therapy; herpes genitalis; herpes simplex virus; laboratory diagnostics; prophylaxis

Year:  2016        PMID: 28017972      PMCID: PMC5177552          DOI: 10.1055/s-0042-116494

Source DB:  PubMed          Journal:  Geburtshilfe Frauenheilkd        ISSN: 0016-5751            Impact factor:   2.915


  66 in total

1.  2014 UK national guideline for the management of anogenital herpes.

Authors:  Raj Patel; John Green; Emily Clarke; Kanchana Seneviratne; Naomi Abbt; Ceri Evans; Jane Bickford; Marian Nicholson; Nigel O'Farrell; Simon Barton; Mark FitzGerald; Elizabeth Foley
Journal:  Int J STD AIDS       Date:  2015-04-09       Impact factor: 1.359

2.  A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group.

Authors:  A G Langenberg; L Corey; R L Ashley; W P Leong; S E Straus
Journal:  N Engl J Med       Date:  1999-11-04       Impact factor: 91.245

3.  Latent herpes simplex virus in spinal ganglia of mice.

Authors:  J G Stevens; M L Cook
Journal:  Science       Date:  1971-08-27       Impact factor: 47.728

Review 4.  Antigenic differences between HSV-1 and HSV-2 glycoproteins and their importance for type-specific serology.

Authors:  T Bergström; E Trybala
Journal:  Intervirology       Date:  1996       Impact factor: 1.763

5.  Value of herpes simplex virus type-specific serology: a case report.

Authors:  J Bentley; A P Neubauer; A Sauerbrei
Journal:  J Clin Virol       Date:  2012-04-01       Impact factor: 3.168

6.  Polymerase chain reaction for detection of herpes simplex virus (HSV) DNA on mucosal surfaces: comparison with HSV isolation in cell culture.

Authors:  Anna Wald; Meei-Li Huang; David Carrell; Stacy Selke; Lawrence Corey
Journal:  J Infect Dis       Date:  2003-10-31       Impact factor: 5.226

7.  Helicase-primase inhibitor pritelivir for HSV-2 infection.

Authors:  Anna Wald; Lawrence Corey; Burkhard Timmler; Amalia Magaret; Terri Warren; Stephen Tyring; Christine Johnston; John Kriesel; Kenneth Fife; Lawrence Galitz; Susanne Stoelben; Meei-Li Huang; Stacy Selke; Hans-Peter Stobernack; Helga Ruebsamen-Schaeff; Alexander Birkmann
Journal:  N Engl J Med       Date:  2014-01-16       Impact factor: 91.245

8.  Increasing proportion of herpes simplex virus type 1 as a cause of genital herpes infection in college students.

Authors:  Craig M Roberts; John R Pfister; Scott J Spear
Journal:  Sex Transm Dis       Date:  2003-10       Impact factor: 2.830

Review 9.  Third trimester antiviral prophylaxis for preventing maternal genital herpes simplex virus (HSV) recurrences and neonatal infection.

Authors:  L M Hollier; G D Wendel
Journal:  Cochrane Database Syst Rev       Date:  2008-01-23

Review 10.  Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention.

Authors:  Elena Anzivino; Daniela Fioriti; Monica Mischitelli; Anna Bellizzi; Valentina Barucca; Fernanda Chiarini; Valeria Pietropaolo
Journal:  Virol J       Date:  2009-04-06       Impact factor: 4.099

View more
  11 in total

1.  In Vitro and In Vivo Activity, Tolerability, and Mechanism of Action of BX795 as an Antiviral against Herpes Simplex Virus 2 Genital Infection.

Authors:  James Hopkins; Tejabhiram Yadavalli; Rahul Suryawanshi; Farreh Qatanani; Ipsita Volety; Ram Koganti; Aqsa Iqbal; Deepak Shukla
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

2.  RUNX Binding Sites Are Enriched in Herpesvirus Genomes, and RUNX1 Overexpression Leads to Herpes Simplex Virus 1 Suppression.

Authors:  Daniel J Kim; William Khoury-Hanold; Priyanka Caroline Jain; Jonathan Klein; Yong Kong; Scott D Pope; William Ge; Ruslan Medzhitov; Akiko Iwasaki
Journal:  J Virol       Date:  2020-10-27       Impact factor: 5.103

Review 3.  Non-HPV Perianal and Anorectal Sexually Transmitted Viral Infections.

Authors:  Margarita Murphy; Gabriel Ryan Chedister; Virgilio George
Journal:  Clin Colon Rectal Surg       Date:  2019-09-06

4.  Surgical excision of a large, verrucous, scrotal mass in a patient with HSV-2 and HIV-1 co-infection.

Authors:  Eva Luderowski; Trinity Bivalacqua; Nikolai Sopko
Journal:  Urol Case Rep       Date:  2018-05-24

5.  Acquired Hemophagocytic Lymphohistiocytosis Associated With Disseminated Herpes Simplex Virus in Immunocompetent Host.

Authors:  Michael Schwartz; Courtney O'Brien; Nischal Raya; Nancy Reau
Journal:  ACG Case Rep J       Date:  2019-08-21

Review 6.  Emerging paradigms of viral diseases and paramount role of natural resources as antiviral agents.

Authors:  R Sagaya Jansi; Ameer Khusro; Paul Agastian; Ahmed Alfarhan; Naif Abdullah Al-Dhabi; Mariadhas Valan Arasu; Rajakrishnan Rajagopal; Damia Barcelo; Amal Al-Tamimi
Journal:  Sci Total Environ       Date:  2020-11-07       Impact factor: 7.963

7.  Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.

Authors:  Larissa Henze; Christoph Buhl; Michael Sandherr; Oliver A Cornely; Werner J Heinz; Yascha Khodamoradi; Til Ramon Kiderlen; Philipp Koehler; Alrun Seidler; Rosanne Sprute; Martin Schmidt-Hieber; Marie von Lilienfeld-Toal
Journal:  Ann Hematol       Date:  2022-01-07       Impact factor: 3.673

8.  A chemical method for generating live-attenuated, replication-defective DNA viruses for vaccine development.

Authors:  Dabbu Kumar Jaijyan; Kavitha Govindasamy; Moses Lee; Hua Zhu
Journal:  Cell Rep Methods       Date:  2022-09-08

Review 9.  Inflammatory pseudotumor associated with HSV infection of rectal vascular endothelium in a patient with HIV: a case report and literature review.

Authors:  Shi Bai; Justin A Maykel; Michelle X Yang
Journal:  BMC Infect Dis       Date:  2020-03-19       Impact factor: 3.090

10.  Assessment of Two Novel Live-Attenuated Vaccine Candidates for Herpes Simplex Virus 2 (HSV-2) in Guinea Pigs.

Authors:  Jonathan D Joyce; Anant K Patel; Brandie Murphy; Daniel J J Carr; Edward Gershburg; Andrea S Bertke
Journal:  Vaccines (Basel)       Date:  2021-03-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.